Managing IP is part of the Delinian Group, Delinian Limited, 8 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Netherlands: Supreme Court rules on role of description in claim interpretation

Resolution Chemicals v AstraZeneca B.V. and Shionogi (Supreme Court of The Netherlands, The Hague, June 8 2018) deals with the extent of protection that is conferred by patent EP0521471 (EP 471), for rosuvastatin, a new cholesterol inhibitor.

Claim 1 of EP 471 does not claim the active ingredient of rosuvastatin (i.e. the rosuvastatin anion), but "the compound [rosuvastatin, described using its molecular formula] acid or a non-toxic pharmaceutically acceptable salt thereof''.

Resolution took the position that the feature "or a non-toxic pharmaceutically acceptable salt thereof" in claim 1 must be interpreted to only comprise the salts mentioned in paragraph [0007] of the patent, stating that "the term "a non-toxic pharmaceutically acceptable salt" refers to a salt in which the cation is an alkali metal ion, an alkaline earth metal ion, or an ammonium ion". Hence, claim 1 must be interpreted more strictly than the literal claim wording gives rise to, and rosuvastatin zinc is outside the scope.

AstraZeneca argued that the average skilled person, taking into account his general professional knowledge, would take paragraph [0007] to merely provide a non-exhaustive list of suitable salts, and that "a non-toxic pharmaceutically acceptable salt" should be understood to include the zinc salt.

The district court concluded that the skilled person would presume that the list of salts in paragraph [0007] was a conscious choice by the patentee and thus construe this paragraph as a limiting definition. It therefore ruled that the zinc salt was not within the scope of EP 471.

The Court of Appeal reversed this decision, and ruled that the average skilled person would have understood that the inventive idea does not reside in identifying suitable salt forms, but in providing a new cholesterol inhibitor having a better biological activity than existing compounds. Accordingly, he would not interpret the patent to "waive'' protection for salts of rosuvastatin other than those mentioned in [0007].

The Supreme Court rejected Resolution's complaint that the Court of Appeal had given more weight to the "essence of the invention'' than what is written in the description and affirmed the Court of Appeal's decision, indicating that it explained the patent claims in light of the common general knowledge of the average skilled person. In addition to this, it also addressed the contribution of rosuvastatin to the art, the role of salt forms in a pharmaceutical rosuvastatin composition, and the fact that EP 471 as a compound patent conferred absolute product protection. It further indicated that, when finding a fair balance according to the Protocol to Article 69 of the European Patent Convention, weight must be given to the skilled person's opinion on whether there are valid reasons for a limitation of the scope of protection. This decision indicates that the waiver doctrine as formulated in the Van Bentum v Kool decision of 2002 no longer has an independent significance as a separate test.


Annemiek Tepper

V.O.Carnegieplein 5, 2517 KJThe HagueThe NetherlandsTel: +31 70 416 67 11Fax: +31 70 416 67

more from across site and ros bottom lb

More from across our site

We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
Sukanya Sarkar shares her thoughts on this year’s annual meeting in Singapore, where debates ranged from AI opportunities to improving law firm culture
The court’s ruling is a good reminder that US parties aren’t guaranteed attorney fees just because they win, say sources
With business confidence in a shaky state, Rachel Tong and Lisa Yong of Rouse discuss how in-house IP teams can manage their trademark portfolios through uncertain times
The Court of Appeal had stern words for Med-El’s representatives after they highlighted a deputy judge’s background as a solicitor
Funders and NPEs say asserting patent portfolios can minimise risk at the USPTO’s PTAB, where procedure remains a controversial topic
The US Supreme Court’s ruling wasn’t a surprise and reflects a trend that had already been bubbling away for a while, say tech and pharma counsel
Previous attempts at major transatlantic tie-ups have failed, so lawyers will keep their eyes firmly on Allen & Overy’s grand plans
INTA CEO Etienne Sanz de Acedo shares his plans if he were to win the EUIPO leadership race and says his application does not affect his INTA role
The French finance minister told António Campinos the timing of an EPO event in Lisbon could be seen as interference in the EUIPO leadership race